The INCI name for the compound used in published angiogenesis and hair research is 2-Deoxy-D-Ribose. Products containing this ingredient should list it under that exact name on their INCI declaration. "Deoxyribose" is less specific than "2-Deoxy-D-Ribose" and does not identify the compound with the same precision used in the published literature. Others use vague descriptors like "sugar extract" or do not list the compound separately from a proprietary blend. None of these alternatives allow you to confirm that the specific compound with the published research profile is what is in the formula.

INCI listing as "2-Deoxy-D-Ribose" is the minimum standard for verifying that the active is correctly identified. For a fuller explanation of how to use the INCI list to evaluate any cosmetic ingredient, the article on why INCI order tells you more than the ingredients list is worth reading first.

The published research on 2dDR uses a range of concentrations depending on delivery format and study, and none of them is a precise match for a 2% aqueous serum. The Anjum 2024 Frontiers in Pharmacology study, the first and only hair-specific animal model paper on 2dDR, used a comparatively low experimental gel concentration, in the region of 0.1-0.2%. Separately, the earlier wound-healing dressing research from the Sheffield group, including Azam 2019 and Dikici 2020, loaded 2dDR into solid alginate or fibre dressings at 5-10% w/v, a different delivery format that isn't directly comparable to a liquid serum concentration.

Unlike high-molecular-weight peptides such as PTD-DBM, where raw material cost makes higher concentrations commercially challenging, 2-Deoxy-D-Ribose is an inexpensive compound, so cost isn't a meaningful barrier to formulating at any concentration in this range. A product claiming to be a 2dDR hair serum while declining to state its concentration at all should prompt the question of why, since there's no cost reason to hide it, whatever figure is chosen.

Some products list 2dDR alongside five or ten other actives in a "hair growth complex" or similar formulation. This approach is not inherently wrong, but it creates an attribution problem: if a multi-ingredient serum produces any visible change, there is no way to know whether 2dDR, one of the other actives, or a combination is responsible. It also typically means that each active is present at a lower concentration than if it were the sole active, since the formula has to distribute between multiple ingredients.

A standalone formulation (where 2-Deoxy-D-Ribose is the principal active in a simple carrier) allows concentration to be maximised, INCI position to be clearly interpreted, and the rationale for any observed effect to be attributed with more confidence. It also allows combination with other serums (copper peptides, Wnt pathway compounds) in a controlled way, rather than having the combinations decided in advance by the formula.

2-Deoxy-D-Ribose is water-soluble and requires no specialised solvents for incorporation into an aqueous formula. A glycol-free aqueous carrier is the appropriate format for a scalp serum: propylene glycol and butylene glycol are effective solvents but add penetration-enhancing properties that interact unpredictably with microneedling, and some users find them sensitising on repeated application. DMSO would be unnecessary for 2dDR (it dissolves readily in water) and its non-selective penetration enhancement creates its own complications for anyone running a multi-product protocol.

A simple carrier (water, glycerin, Sodium Hyaluronate (hyaluronic acid), a standard preservative system) is both sufficient and preferable. Hyaluronic acid (Sodium Hyaluronate) at a meaningful concentration contributes hydration to the scalp surface and supports the serum's texture and application experience without any penetration-enhancing properties that could complicate co-application with other actives. A short, legible formula keeps the carrier readable and avoids obscuring the active.

The research on 2dDR for hair loss is pre-clinical: wound healing models, in vitro angiogenesis studies, and one animal model of androgenic alopecia. No completed human clinical trials exist. A brand selling a 2dDR serum that describes it as "clinically proven," "regrows hair," or makes unqualified efficacy claims may be overstating the current evidence base and, in the case of a UK cosmetic, making claims that extend beyond what cosmetics regulation permits.

Accurate claims language for a 2dDR cosmetic looks like: "research suggests," "in that animal model," "formulated to support the perifollicular vascular environment." Calibrated language is not a sign of product weakness. As covered in the article on what is a cosmetic vs a medicine, it is what regulatory compliance for a pre-clinical active actually requires. A brand that overclaims here is telling you something about how carefully it approaches everything else.

The category of dedicated standalone 2dDR hair serums is small. Most products referencing 2-Deoxy-D-Ribose in a hair context either include it as a secondary ingredient in a multi-active formula, do not disclose the concentration, or are wound dressing and tissue repair products from the original Sheffield research context rather than scalp serums. A product that meets all five criteria above is rare.

AmpleLab's 2% 2dDR Hair Serum is a standalone formulation with 2-Deoxy-D-Ribose as the stated 2% active, clearly listed in the INCI, in a glycol-free aqueous carrier, UK-formulated, and with claims language calibrated to the pre-clinical evidence. At the time of writing, we are not aware of another UK-based standalone 2dDR hair serum available with an explicitly stated concentration and equivalent formulation disclosure.

AmpleLab's 2% 2dDR Hair Serum is a cosmetic formulation registered on the UK SCPN. It is not a medicine and is not intended to diagnose, treat, cure, or prevent any condition. The research referenced is pre-clinical; no clinical hair regrowth claims are made.

AmpleLab.